Conclusions
diabetic
Our cumulative results indicate that auto-BM-MNC and allo-WJ-MSCs are safe and may trigger angiogenesis, restore blood circulation to ischemic sites, and promote tissue regeneration and functional recovery to reduce the severity of CLTI in diabetic patients. Nevertheless, the therapeutic benefit was more noticeable in a shorter time with allo-WJ-MSCs. Thus, our pilot is clinically relevant as it highlights the possible use allo-WJ-MSCs as a novel therapeutic approach, which could be part of the comprehensive management of CLTI in no-option patients.